 |
|
|
||||||||||||||
 |
|
|
Gazing into the Future
2009-Oct-20 — While many other diagnostic companies at the vanguard of personalized medicine look at patients' genetics, Tethys instead looks at a series of biomarkers in the blood to determine the likelihood that someone will develop type 2 diabetes within five years. Unlike the genetic make-up of a patient, which doesn't change, Urdea says the information provided by the PreDx test offers insight into biological changes that can signal the onset of diabetes before it happens. This ability gives doctors a way to identify high-risk patients in time so that lifestyle changes and drug therapies can be used to prevent development of the disease.
Edward Kersh, chief of cardiology at St. Luke's Hospital in San Francisco, began using the test in June. When the PreDx test shows a patient to be at high risk for developing diabetes, he says he refers them to the hospital's diabetes clinic for education and to help alter their lifestyles. Traditionally, though, he says getting patients to alter their lifestyle is a challenge — only about 10 percent do so over the long term. Though it's too early to tell, he thinks the PreDx test results will prove to be powerful motivators. "When the patient sees it in black and white on a piece of paper and reads it, they say, 'You mean I'm going to have diabetes in five years? What can I do about it?'" says Kersh. "You can X, Y, and Z, lose weight, exercise more.' They become very motivated to do it."
Read the full story here.< Back
Jul 22, 2010
Tethys Raises $33 Million
Tethys Bioscience, Inc., announced today that the company has recently raised $33 million, comprising $23 million of venture financing and a $10 million working capital loan.
Jul 14, 2010
Diabetes Risk, on a Scale of 1 to 10
A new test is transforming the way some doctors diagnose and treat their patients.
(Technology Review)
Jul 1, 2010
PreDx® featured on CBS Interactive's Smartplanet
CBS Interactive smartplanet video segment focuses on the impact of the PreDx® Diabetes Risk Score on the physician and patient.
Jun 24, 2010
Tethys Announces Issuance of Key Patent Relating to PreDx™ Diabetes Risk Score Test
United States Patent and Trademark Office grants patent to Tethys. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition.
Nov 9, 2009
Tethys Bioscience Raises $25 Million in Series D Financing
The financing round is led by aeris Capital with George Rehm taking a seat on the Tethys board.
Oct 20, 2009
Gazing into the Future
(Journal of Life Sciences, Fall 2009)